MELD & MELD 3.0 In Liver Transplantation

What Is MELD?

The Model for End-Stage Liver Disease (MELD) score was originally developed at the Mayo Clinic to predict survival in patients undergoing TIPS for complications of portal hypertension.^[8] It was later adopted—after rigorous validation—as the primary tool for prioritizing adult candidates on the liver transplant waiting list in the United States.

For adults (age 12 and older), MELD (and now MELD 3.0) is used by OPTN/UNOS to assign priority for liver allocation. A higher score corresponds to a higher predicted risk of dying within three months without a transplant, and therefore a higher priority for organ offers.^[2][3][6]

Key points:

• MELD is based primarily on objective laboratory tests.
• The score historically ranges from 6 (least ill) to 40 (most ill), though MELD 3.0 can generate values higher than 40 in modeling studies.^[2][11]
• It is recalculated frequently (every few days to months depending on illness severity) while the patient is on the waiting list.
• It is designed to reflect risk of three-month mortality, not long-term prognosis.

How MELD Is Calculated: Labs & Score Range

The traditional MELD score uses three core laboratory values:

• Serum bilirubin (how well the liver clears bile)
• Serum creatinine (kidney function)
• INR (blood clotting, reflecting liver synthetic function)

For allocation purposes, these laboratory results are plugged into a logarithmic formula that generates a score typically between 6 and 40. Creatinine and bilirubin are “capped” at upper and lower limits; creatinine may be adjusted in patients on dialysis. The exact mathematical formula is handled by the official calculators and transplant center software, so patients and families rarely need to compute it themselves.^[2][8]

Important practical points:

• Your MELD score is only as accurate as your most recent labs—hence the frequent blood tests while you are listed.
• The “floor” of the score is 6, even if the lab values would mathematically generate a lower number.
• The “ceiling” is traditionally 40 in the allocation system, although modeling work shows that MELD 3.0 can meaningfully distinguish risk beyond 40.^[11]

The official OPTN MELD calculator is publicly available online, and many centers have a version embedded in their clinical systems.^[2]

From MELD To MELD-Na To MELD 3.0

Over time, clinicians recognized that some important predictors of mortality were missing from the original MELD formula. Two major refinements followed:

• MELD-Na: adds serum sodium to improve prediction, especially in patients with hyponatremia and refractory ascites.^[10]
• MELD 3.0: a newer model that incorporates sex and albumin—along with updated lab coefficients—to improve accuracy and reduce sex-based disparities in transplant access.^[4][5][9]

In a large analysis, MELD 3.0:

• Predicted waitlist mortality more accurately than MELD-Na (slightly higher C-statistic).
• Correctly reclassified nearly 9% of patients who died into a higher priority tier, improving their simulated access to transplant.
• Reduced the survival disadvantage previously seen in women compared with men on the waitlist.^[4][9]

More recent work suggests that MELD 3.0 scores above 40 continue to stratify risk without harming post-transplant outcomes, supporting discussion about “uncapping” the score for allocation in certain settings.^[11]

MELD Exceptions & Special Situations

MELD (even MELD 3.0) does not capture every type of risk. Some conditions carry a high risk of death or dropout from the waiting list but do not always generate a high calculated MELD score. For these patients, transplant teams can request a MELD exception score through OPTN/UNOS review boards.^[6][12]

Common examples include:

• Hepatocellular carcinoma (HCC) within specific size and number criteria
• Cholangiocarcinoma under strict protocols
• Hepatopulmonary syndrome and portopulmonary hypertension
• Refractory complications with relatively preserved lab values

OPTN publishes detailed guidance on how exception scores are granted and how they relate to the median MELD at transplant (MMaT) in a region. Many oncology-related exceptions are now anchored to MMaT-based policies to maintain national equity.^[6][12]

For patients, this often translates to two numbers:

• Your calculated MELD 3.0 from labs.
• Your exception MELD (if granted), which may be higher to reflect additional risk not captured in the formula.

What Your MELD Score Means On The Waiting List

In practical terms, MELD is a way of ranking the urgency of transplant among people waiting for a liver. A higher score means:

• Greater risk of dying in the next three months without transplant
• Greater priority for available deceased donor livers
• More frequent laboratory monitoring and clinical contact

Patient-friendly resources from major centers explain that MELD scores typically range from 6 to 40, and that people with scores in the 30–40 range often receive offers more quickly when an organ becomes available—though exact wait times vary by region, blood type, donor availability, and individual factors.^[3][7][13]

Studies of survival benefit show that patients with MELD scores above about 10–15 begin to gain net life-years from transplantation, and that benefit increases as MELD rises—up to very high scores in modern series.^[7][11]

Median MELD At Transplant (MMaT)

To keep exception policies fair across the country, OPTN tracks the median MELD at transplant (MMaT) for each donor hospital. This number represents the typical MELD (or MELD exception) of patients who actually receive livers in that location over a specified time period.^[10][16]

MMaT is updated periodically—for example, new MMaT values went into effect across the United States in September 2025—and is used as a reference point for many adult MELD exception policies.^[16]

For a patient with an exception diagnosis like HCC, the policy might grant an exception score equal to “MMaT minus 3,” or ensure that the exception never falls below a floor (e.g., MELD 15) even if MMaT changes. This keeps exception candidates aligned with the local level of illness at which most people actually receive transplants.^[6][12]

Practical Tips For Patients & Families

MELD can feel frightening, but it is also a powerful tool to get help to the people who need it most. Some practical suggestions:

• Keep a simple record of your MELD trend over time and bring questions to each clinic visit.
• Ask your team which version they are using (MELD-Na vs MELD 3.0) and how often your labs are repeated.
• Know your “triggers” for calling the team (new confusion, bleeding, severe abdominal pain, infections, fainting).
• Take medications exactly as prescribed, especially diuretics, lactulose, and any treatments related to kidney function.
• Stay in close contact with the transplant center about new hospitalizations, falls, or major changes in symptoms.
• Focus on what you can control: nutrition, mobility, infection prevention, and support systems.

Patient Story: “Watching My MELD Climb”

David is a 49-year-old man with decompensated cirrhosis due to alcohol-related liver disease who has been abstinent for over a year. When he was first evaluated for transplant, his MELD 3.0 was 14. He felt tired, but he was still working part-time and walking daily.

Over the next eight months, he developed more ascites, needed higher diuretic doses, and had one episode of variceal bleeding. His creatinine crept up, his sodium drifted down, and his albumin dropped. His MELD 3.0 slowly climbed into the low 20s.

His team explained that each change in the labs was reflected in the score—that MELD 3.0 was “listening” to his liver, his kidneys, and his blood chemistry. As his score rose, his blood tests became more frequent and the transplant coordinators checked in more often. His transplant center also reviewed whether he qualified for any exception points (he did not).

When David’s MELD reached the high 20s, he started getting called about “backup offers.” Eventually, with a MELD 3.0 of 31, he received an organ offer that went forward. His transplant was uneventful, and he gradually returned to an active life. Looking back, he describes MELD as “the scoreboard that told my team how urgent things were,” not a judgment of his character or effort.

References

1. AASLD Liver Fellow Network. Why do we use the model for end-stage liver disease (MELD) score? Historical overview and rationale for the MELD score and its role in liver transplant allocation.
2. OPTN. MELD Calculator. Official calculator used in U.S. liver allocation, with details on lab caps, dialysis rules, and age criteria.
3. Mayo Clinic. MELD score – Liver disease. Patient-focused explanation of MELD, its score range, and how it affects transplant timing.
4. Kim WR et al. MELD 3.0: The model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887–1895.e4. Original MELD 3.0 development paper describing inclusion of sex and albumin and improved mortality prediction.
5. Verna EC, Indolfi G. Liver transplantation. N Engl J Med. 2023;389:1984–1996. Comprehensive review of liver transplantation, including the role of MELD 3.0 in modern allocation systems.
6. OPTN. Adult MELD Exception Review Guidance (updated July 2025). Detailed policy guidance on MELD exception requests, review board processes, and use of MMaT-based exception scores.
7. NIDDK. The Liver Transplant Process: Preparing for a Transplant. Patient-friendly description of evaluation, waiting list placement, and selection for liver transplant.
8. Kamath PS et al. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805. Classic review of the original MELD model and its validation in predicting outcomes in portal hypertension and liver disease.
9. AASLD. Updated model reduces liver transplant disparities for women (MELD 3.0). Summary of how MELD 3.0 improves equity in transplant access for women.
10. MDCalc. MELD-Na score (UNOS/OPTN). Clinical calculator and summary of MELD-Na, highlighting the role of sodium in risk prediction.
11. Kim WR et al. Mortality in patients with end-stage liver disease above model for end-stage liver disease (MELD) score 40. Hepatology. 2023. Shows that MELD 3.0 scores above 40 continue to stratify mortality without harming post-transplant outcomes.
12. OPTN. Adult MELD Exceptions for Transplant Oncology (2025). Guidance on MELD exceptions in transplant oncology, including HCC and colorectal liver metastases, anchored to MMaT.
13. UPMC. Understanding MELD Score for Liver Transplant. Patient-friendly explanation of MELD ranges and what they mean for waiting list priority.
14. OPTN. Updated median MELD at transplant (MMaT) scores in effect Sept. 25, 2025. Announcement and explanation of updated MMaT values used for adult MELD exception referencing.